Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Q-Linea, Audiocast, Q2'26

By Inderes7/10/2026, 11:00 AM
Q-Linea

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Stuart Gander
00:01 - 18:45

Hello and thank you everyone for joining during the summer here for Q-linea's second quarter report; you have Stuart Gander, the CEO and President, speaking, and I'm joined by our new CFO, Annika Blondeau Henriksson, who will come on later to speak to our financials. The usual disclaimer here, which we'll take as read and understood going forward, and our agenda tracks to our previous quarterly readouts here. I will spend a little bit of time talking to the commercial update in the market and how we see things unfolding with a focus on the US market. Then we'll speak to the outlook through the year, some of the big things happening and what our operational priorities are. Before I turn it over to Annika to talk to our financial performance through the quarter and obviously come back around to questions and answers. All right. So for those who only have a few minutes. Joining us today, the key messages that I would like you to take home are as follows. We did ship out five ASTar instruments during the quarter. I will provide an update on how that translates into activities on the ground, contracting, and test pull-through as we go forward. We did, as many of you will know, get approval from the FDA for our expanded menu, which now is definitively the leader in the market in terms of the panel of drug and drug combinations that it offers to our customers. And the reception from the pipeline of customers with whom we've been speaking now for some time has been very positive. For those customers in the US who are live with ASTar on our version one menu, we've now gone back around and upgraded their software. So, the last of those have now been completed. We expect that to have an impact on those same customers in terms of pull-through, as it unlocks more of the menu for their usage. There is a little bit of delay there in terms of the timing as they need to update their clinical protocols to make those combinations available to all the physicians. But that is happening more or less as we speak. The other thing that we're very excited about is the global expansion I've been speaking to for the last couple of updates here, which is well underway. We completed four new distribution agreements in new markets. I will speak to those. We have a queue of other partners lined up behind them. As you may recall, we are taking a selective approach to signing up new partners, rather than going everywhere. Rather than pushing ourselves into a market, we are basically waiting for distributors to come to us with customers already lined up. And then, it makes for a much quicker, certainly more commercially informed conversation with the customer and the distributor from the get-go. So we do expect that these new markets will generate business in the foreseeable future. And then finally, Annika will speak to this. We have had a pretty marked improvement in our year-on-year operating income that is driven by the impact of the cost-reduction programs we have been speaking to regularly. We are pleased to say that we have successfully completed now the last restructuring and the move to a single site in Sweden. So we can now see that impacting the lower burn rate. So those are the key messages for those who are new to these presentations. Just a quick orientation. Q-linea AB is a developer of a diagnostic instrument for rapid antimicrobial susceptibility testing. We consider it to be the leader in the field. Notably, very strong clinical performance, as I mentioned before, it also has been designed with the lab in mind. It is fully random and continuous access, very easy to use for the lab, and delivers a response for the clinician to act on the patient within six hours of starting the test. As we have talked about before, we see this rapid test market as effectively an upgrade to the current standard of care for patients. That is firstly going towards blood infection patients, where high criticality blood infections lead to sepsis. If it is not treated accurately, there are more critical infections in hospitals that we expect to be able to address in time. I will speak to that a little bit later as we are actually launching a product in the back half of this year that will reach out to those non-blood patients as well. So we see this market starting to emerge here. And ultimately, when these patients migrate over to an improved standard of care, we see this as up to a $1 billion market segment that we are activating. And where are we in that process? Similar pictures we've shared before. So we look at it basically in phases of the pipeline. Developing the upfront of the pipeline, you could say, is relatively stable. It continues to grow. But as I mentioned, we have a large number of customers in the US who are waiting for our V2 that is now on the market. So we've really focused on curating and cultivating those relationships. And then the growth is being driven here by new markets coming on stream, the distributors and so on that I mentioned. And then obviously we are keen to move those evaluations and contract discussions forward into contracted ASTar systems. We had a few more contracts in the quarter. And notably, those five instruments that I mentioned from the contracts have been shipped and set up. So we now have 21 active ASTar instruments in clinical use. And you can see the growth here on rolling 12-month consumables revenue as they generate test results. I would say that we continue to see growth in the same instrument usage, month to month, quarter to quarter, with a particular focus on Italy, where we have a sizable installed base. We are the leader in that market. We are pleased to see that customers continue to use it more as they get more comfortable with it. There is still a lot of work we can do to make sure that all Italian patients have access to rapid AST; on the US side, as I mentioned, the new menu should unlock some volume for existing customers, but US growth will be driven primarily from signing on new contracts, which we are pushing forward with now. On the US side, as I mentioned at the start of the call, it is very clear to everyone that the menu available for a clinician on ASTar is far superior to anything else that is available here. You see a graphic basically showing an overlay of the ASTar menu against the two available competitors in the market, with all the grey cells being ones that are available on both instruments that are compared and the orange ones being available only on ASTar. And you can see that the sheer number of orange dots here represents a panel that is provided by ASTar. That is far superior to the alternatives. And this is what we hear from customers, especially when we speak with clinicians. At the end of the day, this is the information that a clinician is looking for. And they are looking for an instrument that can give them options, both for escalating a patient whose therapy may not be addressing the infection, or also valuable, de-escalating the patient to a less broad-spectrum, less aggressive antibiotic, perhaps even getting them onto an oral medication and discharged from the hospital. And that generates obviously improved patient experience, but critically, also some significant economic savings for the hospital. So breadth of menu is a key factor. We are very pleased with our expanded menu that is now approved. I would say we made some comments here vis-à-vis competitors. Obviously, they are active in the space. There is lots of room for everyone to grow in this nascent market here. We do see when it comes to competitors that obviously they need to compete on price, given the strength of the ASTar offering. We have full respect for that team as a major player in microbiology. So they continue to sell on the breadth of their portfolio. And Lifescale has indicated their intention to develop a fungal panel in the future. But it is not yet available. Yet. And for those following the market, Accelerate was acquired by Bruker. That platform has not yet been approved by the FDA. So, at the moment, there still remains the usual suspects on the field. And we see ourselves as the clear, established leader also in the US. I talked about the global expansion. Franco Pellegrini is leading our EMEA team that's moving eastwards with some speed now. We quite intentionally started with, firstly, southern Europe and Eastern Europe, expanded to the Middle East through our partnership with Amico. That is now well underway. I will speak to a couple of examples there in a minute. And now we're ready to open up the next layer of the growth path here. Franco has a dozen plus discussions ongoing across Africa and Asia. Some more in the Middle East. And so on. As I mentioned, we have successfully signed a few of those. We are also seeing some very interesting multi-site deployment opportunities that are driven more at the national level. A very interesting one is in Ukraine. We are hoping for some decisions soon here. That is a country with an extremely high need for AST testing. Rapid testing, as you can imagine, is critical given their current context. I am very excited about a project ongoing in Vietnam that should reach a decision within the year. That could be quite significant. And then the aforementioned Middle East as well. Also moving ahead, India and Sri Lanka have also had promising discussions. And it looks like there might be a multi-site opportunity in Sri Lanka where we are evolving with our partner there. So as ever, we can never tell exactly when the timing will be on these, but we do expect to see some new pins in the map and new geographies opening during the back half of this year. Based on all the conversations we are having. By way of example, we've spoken before about the GCC. During the quarter, we were very pleased that two of the national ministries of health have come out with versions of reports based on the evaluations they have been conducting on ASTar. So firstly, the National Guard hospital in Saudi Arabia completed and reported a very successful evaluation that led to NUPCO approval, which is the national procurement authority in Saudi Arabia, giving the green light for ASTar, which does a couple of things. It makes it available now for any of the associated public hospitals to reach out to us or our partner, specifically to start a process for procurement. It has also concretely triggered a process with the hospital that conducted the evaluation. So we are very pleased with that. We expect to see some activity there during the year, and following that, pretty much immediately, two new evaluations have started. Also in Saudi Arabia, in Riyadh and Jeddah, there are additional hospitals lined up behind them. There will probably be a few more initially. We will still want to try the instrument in their labs before going into a purchase process directly, but we would expect to see now more and more of them going directly into purchases as they get comfortable with the major hospitals publishing positive evaluations. Similarly, in Kuwait, the Al Amiri Hospital has published their results, which are very good. Obviously, the geopolitical situation there is fairly intense. So there were some delays in that publication for understandable reasons. But that is now available. It more or less does the same, if you will, as the Saudi process in terms of triggering the procurement pathway, allowing other public hospitals to procure directly now based on that evaluation performance. So we're very pleased with that. The Al-Amiri team has done tremendous work, especially given the ongoing developments in the region. We see further developments in the UAE as evaluations conclude and hospitals look to determine when to deploy these. So we expect several more of these to move forward during the year. So just taking a step back, where and how are we focused? Basically, the usual buckets here on the commercial side. It is really a very strong full court press on that pipeline of customers that told us to give them a ring when we had the V2 approved, which we do now. So we have obviously reached out to all of them. They are, as I said, very pleased with the menu, which has started or restarted a number of concrete conversations on the contracting process that is moving forward. We hope to conclude some of those imminently. We are also moving forward with a different contracting program. We call the verify and adopt program that basically enables our customers to share evaluation data more readily between them. There can sometimes be some hurdles in that process. So we are facilitating that process. Obviously, it is fairly burdensome for a customer to run a full formal evaluation, and that sometimes can become a hurdle in terms of timing and resource availability. We hope that this will remove some of those barriers for customers keen to get going with ASTar, especially now that we have a body of customers with both published and unpublished successful evaluation data that can be shared. So that's part of our general push to reduce cycle times. We don't lack for pipeline as you saw from the data. In fact, we are cautious about growing the pipeline more at this stage. We want to really work on the front end of the pipeline and get ASTar systems out and set up. I have no concern about our ability to get more customers interested. So we are really looking to streamline and smooth evaluation processes. We are working with some major GPOs on contracting that should simplify the process for customers and getting contracted and new suppliers set up, which can sometimes be burdensome for smaller suppliers like us. And of course, that. LIS integration and so on are all part of the program here to. Reduce cycle times. As I mentioned previously, we are working with our existing customers to increase the testing rate. We are pleased that the US customers are using it in line with what was expected. And are very likely to increase now with that expanded menu. As I said, in Italy, there are still some budget-driven practices that have kept testing below the level that we see would be needed for the patients. And that presents an opportunity. We are working with customers to showcase patient examples. Obviously, the clinical benefits and the economic impact from deploying ASTar are clear. Again, the more data we collect, the more we show, the more positive the picture is. We do see that influencing physician behavior and test pull-through in sites on a quarter-by-quarter basis on the clinical side. Regarding the development side. We spoke previously about our planned launch this quarter in Q3 for our isolate non-blood test. We remain on track for that milestone. We are very excited to get that out. That will unlock a significant new pool of patients that we think in the long run will benefit from ASTar. And there are some immediate applications from an RUO perspective that we would expect will already have an impact during the year. So, very exciting development there. I would say another great sign of us being established in the market and being seen as a leader in the space is that now conversations with pharma companies on the next generation of drugs are working very smoothly. We are getting a lot of support. We have signed up six pharma companies now to work on getting their drugs onto our disc. One of the very unique features of ASTar and the design of our consumable is that it's easy to put on new drugs without compromising the menu that's already available. This is not the case for most of our competitors. So we are very excited about bringing some of these novel therapies to ASTar customers and hopefully in the very near future here. And then as ever, we continue to work on our cost of goods, both on the consumable side. I have spoken to that before. We are seeing the impact from earlier initiatives. We have several more queued up here that should impact results through the rest of this year. And of course, on the instrument side as well, now that we have more volumes coming, we are able to work in a focused way on sets of opportunities to reduce the cost of the instrument as we go forward. So I would say good progress there. And that will start to show up as volumes increase through the back half of this year. I will not step too much on Annika's points on the financial side of things, other than the fact that the fruits of our cost discipline are showing here in the reduced run rates. That is at the target. We will keep making sure that we are highly disciplined in where we put our resources. At the same time, we do need to be ready for growth in markets as it comes. So obviously, the back half of the year will more or less involve offsetting incremental cost savings with some targeted deployment of new resources into the growth areas. And on the commercial side of things, the other piece that Annika will speak to is really making sure that we maximize our capital recovery. When we put instruments out in the field, it represents for us a fairly significant investment of capital. So anything we can recover from capital sales or rental fees and so on has a meaningful impact on our cash flow. We are very conscious of that. And you know, customers are willing to work with us in a good way on terms there. So, it goes back to what we are doing there. But I see that will be an area of focus for the back half of this year. So with that, I will turn it over to you.

Annika Blondeau Henriksson
18:48 - 24:34

Thank you, Stuart. So we are turning to the financial highlights for the second quarter of 2026. At the end of the quarter, we had 24 contracted ASTar instruments, compared with 12 instruments a year ago. This reflects the continued expansion of our installed base. While we had no capital sales of instruments recognized during the quarter, we only had rentals. We still generated net sales of 1.5 million, up from half a million in the prior year period. Consumable revenue totaled 1.3 MSEK, representing the vast majority of sales in the quarter and remaining roughly at the same level as in Q1. As we continue to grow, installed base consumable utilization remains a key focus area for us, so we are introducing a new KPI in this interim report. Annualized consumable sales per average contracted instrument on a rolling 12-month basis. We measure then the revenue generated by the installed instrument base, and it serves as an indicator for us of the instrument utilization. So for the trailing 12-month period, the KPI amounted to 266,000 Swedish krona as compared to 278,000 in the comparable period. We foresee that the KPI may fluctuate a bit over time, since consumable sales include sales to evaluation activities, but also new instrument placements as utilization typically ramps up over time following the installation. Operating results improved to -31.3 MSEK, compared to -47.4 MSEK in Q2 of last year. This is a significant improvement of 16 MSEK year-over-year, and it reflects the impact of the cost reduction initiatives that we have taken and implemented over the past year, which we now see have been completed during this quarter. Cash flow from operating activities amounted to -13.1 MSEK, compared to -36.4 MSEK in the prior year quarter. So it's worth noting that the quarter includes a 5 MSEK prepayment for planned instrument inventory replenishment, which impacted our cash flow. We ended the quarter with a net cash position of close to 187 MSEK, which continues to provide us with financial flexibility as we continue to invest selectively in commercial opportunities and keep a disciplined cost structure. On the next slide, we present our development of the operating expenses for the past years in Q2. We have included one-off costs, which have been related to the consolidation of the two sites in Uppsala that has been done during the quarter. So as a result, our current cost base is significantly lower than historical levels, and we expect operating expenses to remain below 11 MSEK per month during the second half of 2026. A key point is that, as mentioned, we target our investment. We make the necessary investments in commercial resources and market development activities. We expend the funds through additional internal efficiencies. And this will allow us to support growth initiatives without materially increasing our overall cost base. Also, the slides present the reduction that we have achieved with reference to employees from Q2 of 2023. We were 149 employees. We are now down to 70 employees at the end of Q2 2026, which has created a more focused and efficient organization aligned with our strategic priorities. Moving on to our four key financial priorities, continued cost discipline is obviously very important at this stage of the company. That is why we believe that we will be able to operate with a cost structure of 11 MSEK per month. We also have stronger capital recovery as a key focus area. It is supposed to drive improved utilization of the installed base, increase consumable revenue per instrument, and generate an increasing share of commercial placements in the market with stronger pull-through potential. We foresee that to be the case in the US market regarding gross margin expansion. We will see, as Stuart mentioned, increasing production volume, but also our continuous efforts and initiatives that we have currently ongoing, and some that have been concluded on manufacturing efficiency; we foresee continuing supply negotiation and sourcing optimization as also on our agenda. And finally, we continue to pursue non-dilutive funding opportunities, also mentioned by Stewart, which include discussions with partners regarding co-funding of future product portfolios and solutions that can help us optimize working capital requirements associated with our future going forward. Commercial expansion. Over to you, Stewart.

Stuart Gander
24:38 - 24:49

I suggest we wrap this up. I know it's summertime. So appreciate everyone who joined during the holidays. We wish everyone a great break, and we will have some more updates in a quarter. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…